Discovery and development of surotomycin for the treatment of Clostridium difficile

Mutations Associated with Reduced Surotomycin Susceptibility in Clostridium difficile and Enterococcus Species

(2015) Hannah M. Adams et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Mode of Action and Bactericidal Properties of Surotomycin against Growing and Nongrowing Clostridium difficile

(2015) Mohammed Zahidul Alam et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Effects of Surotomycin on Clostridium difficile Viability and Toxin ProductionIn Vitro

(2015) Laurent Bouillaut et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Practice Parameters for the Management of Clostridium difficile Infection

(2015) Scott R. Steele et al.   DISEASES OF THE COLON & RECTUM

Spore Cortex Hydrolysis Precedes Dipicolinic Acid Release during Clostridium difficile Spore Germination

(2015) Michael B. Francis et al.   JOURNAL OF BACTERIOLOGY

Structure–Activity Relationship Studies of a Series of Semisynthetic Lipopeptides Leading to the Discovery of Surotomycin, a Novel Cyclic Lipopeptide Being Developed for the Treatment of Clostridium difficile-Associated Diarrhea

(2015) Ning Yin et al.   JOURNAL OF MEDICINAL CHEMISTRY

Clostridium difficile Drug Pipeline: Challenges in Discovery and Development of New Agents

(2015) Angie M. Jarrad et al.   JOURNAL OF MEDICINAL CHEMISTRY

Burden of Clostridium difficile Infection in the United States

(2015) Fernanda C. Lessa et al.   NEW ENGLAND JOURNAL OF MEDICINE

Surotomycin Demonstrates LowIn VitroFrequency of Resistance and Rapid Bactericidal Activity in Clostridium difficile, Enterococcus faecalis, and Enterococcus faecium

(2014) Carmela T. M. Mascio et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Efficacy of surotomycin in an in vitro gut model of Clostridium difficile infection

(2014) C. H. Chilton et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Guidelines for Diagnosis, Treatment and Prevention of Clostridium difficile Infections

(2013) Christina M Surawicz et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Clostridium difficile 027/BI/NAP1 Encodes a Hypertoxic and Antigenically Variable Form of TcdB

(2013) Jordi M. Lanis et al.   PLoS Pathogens

Activity of a Novel Cyclic Lipopeptide, CB-183,315, against Resistant Clostridium difficile and Other Gram-Positive Aerobic and Anaerobic Intestinal Pathogens

(2012) D. R. Snydman et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

In VitroandIn VivoCharacterization of CB-183,315, a Novel Lipopeptide Antibiotic for Treatment of Clostridium difficile

(2012) Carmela T. M. Mascio et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Fidaxomicin Versus Vancomycin for Clostridium difficile Infection: Meta-analysis of Pivotal Randomized Controlled Trials

(2012) Derrick W. Crook et al.   CLINICAL INFECTIOUS DISEASES

Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial

(2012) Oliver A Cornely et al.   LANCET INFECTIOUS DISEASES

Comprehensive analysis of methods used for the evaluation of compounds against Mycobacterium tuberculosis

(2012) Scott G. Franzblau et al.   TUBERCULOSIS

Inactivation of the Lipopeptide Antibiotic Daptomycin by Hydrolytic Mechanisms

(2011) Vanessa M. D'Costa et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

In VitroActivities of CB-183,315, Vancomycin, and Metronidazole against 556 Strains of Clostridium difficile, 445 Other Intestinal Anaerobes, and 56 Enterobacteriaceae Species

(2011) Diane M. Citron et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Fidaxomicin versus Vancomycin forClostridium difficileInfection

(2011) Thomas J. Louie et al.   NEW ENGLAND JOURNAL OF MEDICINE

Daptomycin: From the Mountain to the Clinic, with Essential Help from Francis Tally, MD

(2010) Barry I. Eisenstein et al.   CLINICAL INFECTIOUS DISEASES

Clinical Practice Guidelines for Clostridium difficile Infection in Adults: 2010 Update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA)

(2010) Stuart H. Cohen et al.   INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY

Human Hypervirulent Clostridium difficile Strains Exhibit Increased Sporulation as Well as Robust Toxin Production

(2010) M. Merrigan et al.   JOURNAL OF BACTERIOLOGY

Targeting bacterial membrane function: an underexploited mechanism for treating persistent infections

(2010) Julian G. Hurdle et al.   NATURE REVIEWS MICROBIOLOGY

Recurrent Clostridium difficile infection: A review of risk factors, treatments, and outcomes

(2009) Stuart Johnson   JOURNAL OF INFECTION